Optimal Detection of Fetal Chromosomal Abnormalities by Massively Parallel DNA Sequencing of Cell-Free Fetal DNA from Maternal Blood

Amy J. Sehnert,1 Brian Rhees,1† David Comstock,1 Eileen de Feo,1 Gabrielle Heilek,1‡ John Burke,2 and Richard P. Rava1*

BACKGROUND: Massively parallel DNA sequencing of cell-free fetal DNA from maternal blood can detect fetal chromosomal abnormalities. Although existing algorithms focus on the detection of fetal trisomy 21 (T21), these same algorithms have difficulty detecting trisomy 18 (T18).

METHODS: Blood samples were collected from 1014 patients at 13 US clinic locations before they underwent an invasive prenatal procedure. All samples were processed to plasma, and the DNA extracted from 119 samples underwent massively parallel DNA sequencing. Fifty-three sequenced samples came from women with an abnormal fetal karyotype. To minimize the intra- and interrun sequencing variation, we developed an optimized algorithm by using normalized chromosome values (NCVs) from the sequencing data on a training set of 71 samples with 26 abnormal karyotypes. The classification process was then evaluated on an independent test set of 48 samples with 27 abnormal karyotypes.

RESULTS: Mapped sites for chromosomes of interest in the sequencing data from the training set were normalized individually by calculating the ratio of the number of sites on the specified chromosome to the number of sites observed on an optimized normalizing chromosome (or chromosome set). Threshold values for trisomy or sex chromosome classification were then established for all chromosomes of interest, and a classification schema was defined. Sequencing of the independent test set led to 100% correct classification of T21 (13 of 13) and T18 (8 of 8) samples. Other chromosomal abnormalities were also identified.

CONCLUSION: Massively parallel sequencing is capable of detecting multiple fetal chromosomal abnormalities from maternal plasma when an optimized algorithm is used.

© 2011 American Association for Clinical Chemistry

The American College of Obstetrics and Gynecology Practice Bulletin no. 77, published in 2007, supports the measurement of nuchal translucency and surrogate biochemical markers in all pregnant women in the first trimester to assess the risk of aneuploidy for Down syndrome (1). These screening tests can provide only an inconclusive risk determination; they have nonoptimal detection and high false-positive rates. Today, only invasive methods, including chorionic villus sampling (CVS),3 amniocentesis, or cordocentesis, provide definite genetic information about the fetus, but these procedures are associated with risks to both mother and fetus (2–4). Therefore, a noninvasive means to obtain definite information on fetal chromosomal status is desirable.

Fan et al., in 2008, were the first to suggest counting chromosomes by mapping sequence tags as a potential quantification method for detecting fetal aneuploidy from cell-free DNA (cfDNA) obtained from maternal blood (5, 6). In these studies, massively parallel DNA sequencing of cfDNA obtained from the maternal plasma yielded millions of short sequence tags that could be aligned and uniquely mapped to sites from a reference human genome. The depth of sequencing and subsequent counting statistics determine the sensitivity of detection for fetal aneuploidy (7).

Although 2 recently published reports of studies with larger populations have described the successful use of sequence tag mapping and chromosome counting to detect fetal aneuploidy, these studies focused only on the classification of trisomy 21 (T21) (8, 9).
The algorithms used in these studies appear to be unable to effectively detect other aneuploidies, such as trisomy 18 (T18), that would inevitably occur in a clinical population being offered a commercially available test. In this study, we developed and tested an optimized algorithm from massively parallel sequencing data and demonstrated the potential universality of the sequence tag mapping and chromosome-quantification method for the detection of multiple chromosomal abnormalities.

Materials and Methods

BLOOD SAMPLES AND CLINICAL INFORMATION
The study was conducted by qualified clinical research personnel at 13 US clinic locations between April 2009 and July 2010 under a human participant protocol approved by institutional review boards at each institution. Informed written consent was obtained from each woman before her inclusion in the study.

The protocol was designed to provide blood samples and clinical data to support the development of noninvasive prenatal genetic diagnostic methods. Pregnant women age 18 years or older were eligible for inclusion. For patients undergoing clinically indicated CVS or amniocentesis, blood was collected before performance of the procedure, and fetal-karyotyping results were also collected. Peripheral blood samples (2 tubes or approximately 20 mL total) were drawn from all participants and collected into tubes containing acid citrate dextrose (Becton Dickinson). All samples were deidentified and assigned an anonymous study identification number. Blood samples were shipped overnight to Verinata Health, Inc. (San Carlos, CA) in temperature-controlled shipping containers provided for the study. The time elapsed between blood draw and sample receipt was recorded upon accessioning at the Verinata Health laboratory.

Site research coordinators used the anonymous patient identification number in entering clinical data relevant to the patient’s current pregnancy and history into study case-report forms. Cytogenetic analysis of the fetal karyotype from samples obtained in invasive prenatal procedure was performed per the local laboratories, and these results were also recorded in the study case-report forms. All data obtained on the forms were entered into a clinical database at Verinata Health.

SAMPLE PROCESSING AND SEQUENCING
Cell-free plasma was obtained from individual blood tubes within 24–48 h of venipuncture via centrifugation at 1600g for 10 min, transfer to microcentrifuge tubes, and centrifugation at 16 000g for 10 min to remove residual cells. Plasma from a single blood tube was sufficient for sequencing analysis. cfDNA was extracted from cell-free plasma with the QIAamp DNA Blood Mini Kit (Qiagen) according to the manufacturer’s instructions. Because cfDNA fragments are known to be approximately 170 bp in length (10), a DNA-fragmentation step was not required before sequencing. For the training set samples, we sent cfDNA to Progenys Biosciences to prepare a sequencing library (cfDNA blunt-ended and ligated to universal adapters) and for sequencing on the Illumina Genome Analyzer IIx instrumentation according to the manufacturer’s standard protocols (http://www.illumina.com/). Single-end reads of 36 bp were obtained. Upon completion of the sequencing, all base-call files were transferred to Verinata Health for further analysis. For the test set samples, we prepared the sequencing libraries and carried out the sequencing on the Illumina Genome Analyzer IIx instrument at Verinata Health. For both the training and test sample sets, single-end reads of 36 bp were sequenced.

DATA ANALYSIS AND SAMPLE CLASSIFICATION
Sequence reads of 36 bases in length were aligned to the human genome assembly hg18 obtained from the University of California, Santa Cruz database (http://hgdownload.cse.ucsc.edu/goldenPath/hg18/bigZips/). Alignments were carried out by using the Bowtie short read aligner (version 0.12.5) and allowing for up to 2 base mismatches during alignment (11). Only reads that unambiguously mapped to a single genomic location were included. The genomic sites where reads mapped were counted and included in the calculation of chromosome ratios (see below). Regions on the Y chromosome where sequence tags from male and female fetuses map without any discrimination were excluded from the analysis (specifically, from base 0 to base 2 × 10^6, base 10 × 10^6 to base 13 × 10^6, and base 23 × 10^6 to the end of chromosome Y).

Intrarun and interrun sequencing variation in the chromosomal distribution of sequence reads can obscure the effects of fetal aneuploidy on the distribution of mapped sequence sites. To correct for such variation, we calculate a chromosome ratio, in which the count of mapped sites for a given chromosome of interest is normalized to counts observed on another predetermined chromosome (or set of chromosomes). To identify the optimal chromosome ratio for each chromosome of interest, we reviewed the unaffected subset of the training data (i.e., including only samples with diploid karyotypes for chromosomes 21, 18, 13, and X) and considered each autosome as a potential denominator in a ratio of counts with our chromosomes of interest. We selected denominator chromosomes that minimized the variation of the chromosome ratios within and between sequencing runs. Each chromo-
some of interest was determined to have a distinct denominator (Table 1).

The full training set was then used to set the boundaries for sample classification. The means and SDs of chromosome ratios for the unaffected samples in the training set were determined. For each sample and chromosome of interest, a normalized chromosome value (NCV) was calculated with the equation:

\[
NCV_i = \frac{x_{ij} - \bar{x}_j}{\sigma_j},
\]

where \(\bar{x}_j\) and \(\sigma_j\) are the estimated training set mean and SD, respectively, for the \(j\)-th chromosome ratio and \(x_{ij}\) is the observed \(j\)-th chromosome ratio for sample \(i\). When chromosome ratios are normally distributed, the NCV is equivalent to a statistical \(z\) score for the ratios. No significant departure from linearity was observed in a quantile–quantile plot of the NCVs from unaffected samples. In addition, standard tests of normality for the NCVs failed to reject the null hypothesis of normality. For both the Kolmogorov–Smirnov and Shapiro–Wilk tests, the significance value was >0.05.

For the test set, an NCV was calculated for each chromosome of interest—21, 18, 13, X, and Y—for every sample. To ensure a safe and effective classification scheme, we chose conservative boundaries for aneuploidy classification. For classification of the autosomes’ aneuploidy state, we required an NCV >4.0 to classify the chromosome as affected (i.e., aneuploid for that chromosome) and an NCV <2.5 to classify a chromosome as unaffected. Samples with autosomes that had an NCV between 2.5 and 4.0 were classified as “no call.”

Sex chromosome classification in the test is performed in a somewhat more complex fashion—by sequential application of NCVs for both X and Y. Specifically:

1. If the NCV for Y is greater than −2.0 SDs from the mean of male samples, then the sample is classified as male (XY).
2. If the NCV for Y is less than −2.0 SDs from the mean of male samples and the NCV for X is greater than −2.0 SDs from the mean of female samples, then the sample is classified as female (XX).
3. If the NCV for Y is less than −2.0 SDs from the mean of male samples and the NCV for X is less than −3.0 SDs from the mean of female samples, then the sample is classified as monosomy X, i.e., Turner syndrome.
4. If the NCVs do not fit into any of the above 3 criteria, then the sample is classified as a “no call” for sex.

### Results

#### STUDY POPULATION DEMOGRAPHICS

We enrolled 1014 patients between April 2009 and July 2010. The patient demographic characteristics, the type of invasive procedure, and karyotype results are summarized in Table 2. The mean age of the study participants was 35.6 years (range, 17–47 years), and gestational age ranged from 6 weeks, 1 day to 38 weeks, 1 day (mean, 15 weeks, 4 days). The observed overall incidence of abnormal fetal chromosome karyotypes was 6.8%, with a T21 incidence of 2.5%. Of 946 participants with singleton pregnancies and a karyotype, 906 (96%) showed at least 1 clinically recognized risk factor for fetal aneuploidy before undergoing the prenatal procedure. Even after eliminating the women with advanced maternal age as their sole indication, the data demonstrate a very high false-positive rate for current screening modalities. Ultrasound findings of increased nuchal translucency, cystic hygroma, or another structural congenital abnormality were most predictive of an abnormal karyotype in this cohort.

The distribution of the diverse ethnic backgrounds represented in this study population is also shown in Table 2. Overall, the patients were 63% Caucasian, 17% Hispanic, 6% Asian, 5% multiethnic, and 4% African American. We noted that the ethnic diversity varied substantially from site to site. For example, one site enrolled 60% Hispanic and 26% Caucasian individuals, whereas 3 other clinics located in the same state enrolled no Hispanic participants. As expected, there were no discernible differences in our results with respect to different ethnicities.

#### TRAINING SET DATA

The training set study selected 71 samples from the initial sequential accumulation of 435 samples that were collected between April 2009 and December 2009. All participants with affected fetuses (abnormal karyotypes) in this first series of participants, as well as a random selection of nonaffected individuals with adequate sample and data, were included for sequencing. The clinical characteristics of the patients in the training set were consistent with the overall study demographics summarized in Table 2. The gestational age

<table>
<thead>
<tr>
<th>Chromosome of interest</th>
<th>Numerator (chromosome mapped sites)</th>
<th>Denominator (chromosome mapped sites)</th>
</tr>
</thead>
<tbody>
<tr>
<td>21</td>
<td>21</td>
<td>9</td>
</tr>
<tr>
<td>18</td>
<td>18</td>
<td>8</td>
</tr>
<tr>
<td>13</td>
<td>13</td>
<td>Sum (2–6)</td>
</tr>
<tr>
<td>X</td>
<td>X</td>
<td>6</td>
</tr>
<tr>
<td>Y</td>
<td>Y</td>
<td>Sum (2–6)</td>
</tr>
</tbody>
</table>

Clinical Chemistry 57:7 (2011) 3
Table 2. Patient demographics.

<table>
<thead>
<tr>
<th>Demographic characteristics</th>
<th>Total enrolled (n = 1014)</th>
<th>Training set (n = 71)</th>
<th>Test set (n = 48)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dates of enrollment</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apr 2009 to Jul 2010</td>
<td>Apr 2009 to Dec 2009</td>
<td>Jan 2010 to Jun 2010</td>
<td></td>
</tr>
<tr>
<td><strong>Patients enrolled, n</strong></td>
<td>1014</td>
<td>435</td>
<td>575</td>
</tr>
<tr>
<td><strong>Maternal age</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD), years</td>
<td>35.6 (5.66)</td>
<td>36.4 (6.05)</td>
<td>34.2 (8.22)</td>
</tr>
<tr>
<td>Minimum/maximum, years</td>
<td>17/47</td>
<td>20/46</td>
<td>18/46</td>
</tr>
<tr>
<td>Not specified, n</td>
<td>11</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td><strong>Ethnicity, n (%)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caucasian</td>
<td>636 (62.7)</td>
<td>50 (70.4)</td>
<td>24 (50.0)</td>
</tr>
<tr>
<td>Hispanic</td>
<td>167 (16.5)</td>
<td>6 (8.5)</td>
<td>13 (27.0)</td>
</tr>
<tr>
<td>Asian</td>
<td>63 (6.2)</td>
<td>6 (8.5)</td>
<td>5 (10.4)</td>
</tr>
<tr>
<td>Multiethnic (&gt;1)</td>
<td>53 (5.2)</td>
<td>6 (8.5)</td>
<td>1 (2.1)</td>
</tr>
<tr>
<td>African American</td>
<td>41 (4.0)</td>
<td>1 (1.3)</td>
<td>3 (6.3)</td>
</tr>
<tr>
<td>Other</td>
<td>36 (3.6)</td>
<td>2 (2.8)</td>
<td>1 (2.1)</td>
</tr>
<tr>
<td>Native American</td>
<td>9 (0.9)</td>
<td>0 (0.0)</td>
<td>1 (2.1)</td>
</tr>
<tr>
<td>Not specified, n</td>
<td>9 (0.9)</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td><strong>Gestational age, weeks, days</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>15, 4</td>
<td>14, 5</td>
<td>15, 3</td>
</tr>
<tr>
<td>Minimum/maximum</td>
<td>6, 1/38, 1</td>
<td>10, 0/23, 1</td>
<td>10, 4/28, 3</td>
</tr>
<tr>
<td><strong>No. of fetuses, n</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>982</td>
<td>67</td>
<td>47</td>
</tr>
<tr>
<td>2</td>
<td>30</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>3</td>
<td>2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>Prenatal procedure, n (%)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CVS</td>
<td>430 (42.4)</td>
<td>38 (53.5)</td>
<td>28 (58.3)</td>
</tr>
<tr>
<td>Amniocentesis</td>
<td>571 (56.3)</td>
<td>32 (45.1)</td>
<td>20 (41.7)</td>
</tr>
<tr>
<td>Not specified</td>
<td>3 (0.3)</td>
<td>1 (1.4)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>Not performed</td>
<td>10 (1.0)</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td><strong>Fetal karyotype, n (%)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>46,XX</td>
<td>453* (43.9)</td>
<td>22* (29.7)</td>
<td>7* (14.6)</td>
</tr>
<tr>
<td>46,XY</td>
<td>474* (45.9)</td>
<td>26* (35.1)</td>
<td>14 (29.2)</td>
</tr>
<tr>
<td>47, +21 (both sexes)</td>
<td>25* (2.4)</td>
<td>10* (13.5)</td>
<td>13 (27.1)</td>
</tr>
<tr>
<td>47, +18 (both sexes)</td>
<td>14 (1.4)</td>
<td>5 (6.8)</td>
<td>8 (16.7)</td>
</tr>
<tr>
<td>47, +13 (both sexes)</td>
<td>4 (0.4)</td>
<td>2 (2.7)</td>
<td>1 (2.1)</td>
</tr>
<tr>
<td>45,X</td>
<td>8 (0.8)</td>
<td>3 (4.1)</td>
<td>3 (6.3)</td>
</tr>
<tr>
<td>Complex, other</td>
<td>18* (1.7)</td>
<td>6 (8.1)</td>
<td>2 (4.2)</td>
</tr>
<tr>
<td><strong>Karyotype not available</strong></td>
<td>36 (3.5)</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td><strong>Prenatal screening risks for karyotyped singletons</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nonsequenced (n = 834), n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AMA only (≥35 years)</td>
<td>445 (53.4)</td>
<td>27 (41.5)</td>
<td>21 (44.7)</td>
</tr>
<tr>
<td>Screen positive (trisomy)*</td>
<td>149 (17.9)</td>
<td>18 (27.7)</td>
<td>9 (19.1)</td>
</tr>
<tr>
<td>Increased NT</td>
<td>35 (4.2)</td>
<td>3 (4.6)</td>
<td>5 (10.6)</td>
</tr>
<tr>
<td>Cystic hygroma</td>
<td>12 (1.4)</td>
<td>5 (7.7)</td>
<td>4 (8.5)</td>
</tr>
<tr>
<td>Cardiac defect</td>
<td>14 (1.7)</td>
<td>0 (0.0)</td>
<td>4 (8.5)</td>
</tr>
<tr>
<td>Other congenital abnormality</td>
<td>78 (9.4)</td>
<td>4 (6.2)</td>
<td>3 (6.4)</td>
</tr>
<tr>
<td>Other maternal risk</td>
<td>64 (7.7)</td>
<td>5 (7.7)</td>
<td>1 (2.1)</td>
</tr>
<tr>
<td>None specified</td>
<td>37 (4.4)</td>
<td>3 (4.6)</td>
<td>0 (0.0)</td>
</tr>
</tbody>
</table>

* Includes results of fetuses from multiple gestations.

AMA, advanced maternal age; NT, nuchal translucency.

* Assessed and reported by clinicians.
for the samples in the training set ranged from 10 weeks, 0 days to 23 weeks, 1 day. Thirty-eight patients underwent CVS, 32 underwent amniocentesis, and 1 patient did not have the type of invasive procedure specified (an unaffected karyotype, 46,XY). The patients were 70% Caucasian, 8.5% Hispanic, 8.5% Asian, and 8.5% multiethnic. Six sequenced samples were removed from this set for the purposes of training—4 samples from individuals with twin gestations (further discussed below), 1 sample with T18 that was contaminated during preparation, and 1 sample with fetal karyotype 69,XXX—leaving 65 samples for the training set.

The number of unique sequence sites (i.e., tags identified with unique sites in the genome) increased from $2.2 \times 10^6$ in the early phases of the training set study to $13.7 \times 10^6$ in the latter phases because of improvements in the sequencing technology over this period. To monitor for any potential shifts in the chromosome ratios over this 6-fold range in unique sites, we ran different unaffected samples at the beginning and the end of the study. For the first run of 15 unaffected samples, the mean number of unique sites was $3.8 \times 10^6$, and the mean chromosome ratios for chromosomes 21 and 18 were 0.314 and 0.528, respectively. For the last run of 15 unaffected samples, the mean number of unique sites was $10.7 \times 10^6$, and the mean chromosome ratios for chromosomes 21 and 18 were 0.316 and 0.529, respectively. There was no statistically significant difference in the chromosome ratios over the time of the training set study for chromosome 21 or for chromosome 18.

The training set NCVs for chromosomes 21, 18, and 13 are shown in Fig. 1. These results are consistent with an assumption of normality, in that approximately 99% of the diploid NCVs fall within $\pm 2.5$ SDs of the mean. Of this set of 65 samples, 8 samples with clinical karyotypes indicating T21 had NCVs between 6 and 20. Four samples with clinical karyotypes indicative of fetal T18 had NCVs between 3.3 and 12, and the 2 samples with karyotypes indicative of fetal trisomy 13 (T13) had NCVs of 2.6 and 4. The spread in the NCVs in affected samples is due to their dependence on the percentage of fetal cfDNA in the individual samples.

Similarly to the autosomes, the means and SDs for the sex chromosomes were established in the training set. The sex chromosome thresholds allowed 100% of the male and female fetuses in the training set to be identified.

**TEST SET DATA**

Having established chromosome ratio means and SDs from the training set, we selected a test set of 48 samples from 575 samples collected between January 2010 and June 2010. One of the samples from a twin gestation was removed from the final analysis, leaving 47 samples in the test set. The personnel preparing samples for sequencing and operating the equipment were blinded to the clinical karyotype information. The range of gestational ages was similar to that of the training set (Table 2). Fifty-eight percent of the invasive procedures were CVS, higher than the percentage of the overall procedural demographics, but similar to that of the training set. The participants were 50% Caucasian, 27% Hispanic, 10.4% Asian, and 6.3% African American.

In the test set, the number of unique sequence tags varied from approximately $13 \times 10^6$ to $26 \times 10^6$. For unaffected samples, the chromosome ratios for chromosomes 21 and 18 were 0.313 and 0.527, respectively. The test set NCVs for chromosomes 21, 18, and 13 are shown in Fig. 2, and the classifications are given in Table 3. In the test set, 13 of 13 individuals with clinical karyotypes indicating fetal T21 were correctly identified, with NCVs between 5 and 14. All 8 individuals with karyotypes indicating fetal T18 were correctly identified, with NCVs between 8.5 and 22. The single sample with a karyotype classified as T13 in this test set was classified as a “no call,” with an NCV of approximately 3.

For the test data set, all male samples were correctly identified [including a sample with complex karyotype, 46,XY plus a marker chromosome (unidentifiable by cytogenetics); Table 3]. Nineteen of 20 female samples were correctly identified; 1 female sample was categorized as a “no call.” Two of 3 samples in the test set with a karyotype of 45,X were correctly identified as monosomy X. The third sample was classified as a “no call” (Table 3).
TWINS

Although the method is currently envisioned for use with singleton pregnancies, 4 of the samples initially selected for the training set and 1 of the samples in the test set were from twin gestations. The thresholds we are using could be confounded by the different amounts of cfDNA expected in the setting of a twin gestation. In the training set, the karyotype from one of the twin samples was monochorionic 47,XY,\(\text{H11001}\)\text{21}. A second twin sample was fraternal, and amniocentesis was carried out on each of the fetuses. One of these fetuses had a karyotype of 47,XY,\(\text{H11001}\)\text{21}, whereas the other had a normal karyotype, 46,XX. In both of these cases, the cell-free classification based on the methods discussed above classified the sample as T21. The other 2 twin gestations in the training set were classified correctly as nonaffected for T21 (all twins showed a diploid karyotype for chromosome 21). For the twin gestation sample in the test set, a karyotype was established only for twin B (46,XX); the algorithm correctly classified this patient as nonaffected for T21.

Discussion

In this study, we have optimized the power of massively parallel sequencing for detecting multiple abnormal fetal karyotypes from the blood of pregnant women. To our knowledge, this study is the first to demonstrate 100% correct classification of samples with trisomy 21 and trisomy 18 with an independent set of test data. Even in the case of fetuses with abnormal sex chromosome karyotypes, no sample was incorrectly classified with our algorithm. Importantly, the algorithm also performed well in detecting the presence of T21 in 2 sets of twin pregnancies with at least 1 affected fetus, a result that has not previously been reported. Furthermore, our study examined a variety of sequential samples from multiple centers that not only represented the range of abnormal karyotypes one is likely to witness in a commercial clinical setting but also demonstrated the importance of accurately classifying pregnancies unaffected by common trisomies to address the unacceptably high false-positive rates that occur in prenatal screening today. The data provide valuable insight into the vast potential of this method for use in the future.

An analysis of subsets of the unique genomic sites showed increases in the variance consistent with Poisson counting statistics. Our work builds on the findings with our algorithm.
of Fan and Quake, who demonstrated that the sensitivity of noninvasive prenatal detection of fetal aneuploidy from maternal plasma via massively parallel sequencing is limited only by the counting statistics (7). Because we are collecting information across the entire genome, this method is capable of detecting any aneuploidy or other copy number variation including insertions and deletions. The karyotype for one of our samples had a small deletion in chromosome 11 between q21 and q23 that we observed as an approximately 10% decrease in the relative number of tags in a 25-Mb region starting at q21 when we analyzed the sequencing data in 500-kb bins. In addition, 3 of the samples in the training set had complex sex karyotypes that the cytogenetic analysis revealed to be due to mosaicism. These karyotypes were: (a) 47,XXX[9]/45,X[6], (b) 45,X[3]/46,XY[17], and (c) 47,XXX[13]/45,X[7]. Sample b, which showed some XY-containing cells, was correctly classified as XY. Samples a (from a CVS procedure) and c (from amniocentesis), which a cytogenetic analysis revealed both to be a mixture of XXX and X cells (consistent with mosaic Turner syndrome), were classified as a “no call” and monosomy X, respectively. Further work is warranted to compare the results obtained from sequencing data—not only to cytogenetic results obtained via invasive prenatal procedures (particularly CVS, which can reveal confined placental mosaicism) but also to birth outcomes—to better understand test performance in the setting of such complex cases.

In testing our algorithm, we observed another interesting result for one of the samples from our test set, which had an NCV between −5 and −6 for chromosome 21 (Fig. 2). Although cytogenetic analysis revealed this sample to be diploid for chromosome 21, the karyotype showed mosaicism, with triploidy for chromosome 9: 47,XX,+9[9]/46,XX[6]. Because chromosome 9 is used in the denominator of our algorithm for determining the chromosome 21 ratio (Table 1), that mosaicism lowered the overall NCV value. This result strikingly demonstrates the ability of this algorithm to detect fetal trisomy 9 in this case. In subsequent studies, which we are now conducting, we are using multiple chromosome ratios to ensure correct classification for the chromosomes of interest. In addition, we are establishing normalizing chromosomes for all of the autosomes to increase the probability of detecting rare aneuploidies across the genome.

The conclusion of Fan et al. regarding the sensitivity of these methods is correct only if the algorithms being used are able to account for any random or systematic biases introduced by the sequencing method. If the sequencing data are not properly normalized, the resulting analysis will be inferior to the counting statistics. Chiu et al. noted in their recent report that their measurement of chromosomes 18 and 13 with the massively parallel sequencing method was imprecise and concluded that more research was necessary in order to apply the method to the determination of T18 and T13 (8). The method described by Chiu et al. simply uses the number of sequence tags on the chromosome of interest—in their case chromosome 21—normalized by the total number of tags in the sequencing run. The challenge for this approach is that the distribution of tags on each chromosome can vary from sequencing run to sequencing run, and this variation thus can increase the overall variation of the aneuploidy-detection metric. To compare the results obtained with the Chiu algorithm to the chromosome ratios we describe in this report, we reanalyzed our set of test data for chromosomes 21 and 18 with the method recommended by Chiu et al. (Fig. 3). Overall, we observed a compression in the range of NCVs for chromosomes 21 and 18 separately, as well as a decrease in the detection rate, with 10 of 13 T21 samples and 5 of 8 of T18 samples correctly identified from our test set with an NCV threshold of 4.0 for aneuploidy classification.

Ehrich et al. also focused only on T21 and used the same algorithm as Chiu et al. (9). After observing a shift in their test set z-score metric from the external reference data (training set), they retrained on the test set to establish the classification boundaries. Although this approach is feasible in principle, in practice it would be challenging to decide how many samples would be required for training and how often one would need to retrain to ensure that the classification boundaries were correct. One method
of mitigating this issue is to include in every sequencing run controls that measure the baseline and calibrate for quantitative behavior. We are currently developing such controls and are incorporating them into our future clinical studies.

In conclusion, we have shown that massively parallel sequencing is capable of detecting multiple fetal chromosomal abnormalities from the plasma of pregnant women when the algorithm for normalizing the chromosome-counting data is optimized. Our algorithms for quantification not only minimize random and systematic variation between sequencing runs but also allow for effective classification of aneuploidies across the entire genome, most notably T21 and T18. Larger sample collections are required to further test the algorithm for T13 detection. To this end, we are currently conducting a prospective, blinded, multisite clinical study to further demonstrate the diagnostic accuracy of our methods and to validate the conclusions presented in this report.

Author Contributions: All authors confirmed they have contributed to the intellectual content of this paper and have met the following 3 requirements: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; and (c) final approval of the published article.

Authors’ Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the Disclosures of Potential Conflict of Interest form. Potential conflicts of interest:

Employment or Leadership: A.J. Sehnert, Verinata Health; B.K. Rhees, Verinata Health; D. Comstock, Verinata Health; E. de Feo, Verinata Health; G. Heilek, Verinata Health; J. Burke, Verinata Health; R.P. Rava, Verinata Health.

Consultant or Advisory Role: J. Burke, Verinata Health.


Honoraria: None declared.

Research Funding: None declared.

Expert Testimony: None declared.

Role of Sponsor: The funding organizations played a direct role in the design of the study, the choice of enrolled patients, the review and interpretation of data, and the preparation and final approval of the manuscript.

Acknowledgments: We thank the pregnant women who enrolled in this study, without whom this research could not have been conducted. We also thank the following members of the Verinata Health research team who processed samples and generated the data: Neha Agarwal, Manjula Chinnappa, Gail Chimock, Vivian Nguyen, Saba Parsa, Rochelle Secreto, Jason Sprowl, and Ryan Van Luchene.

Participating study sites and contact persons: Lawrence Platt, MD, Center for Fetal Medicine; James Goldberg, MD, San Francisco Perinatal Associates; Valerie Rappaport, MD, New Mexico Consortium for Perinatal Research (includes Center for Prenatal Development; Timothy Hurley, MD, Pitton Perinatal; Michael Wolfe, MD, University of New Mexico; and Theresa Harper, MD, Perinatal Associates of New Mexico); Meredith Rochon, MD, Lehigh Valley Hospital; Ronald Wapner, MD, Columbia University Medical Center; Alfred Abuhamad, MD, Eastern Virginia Medical School (Norfolk, Newport News, and Virginia Beach locations); Martin Chavez, MD, Winthrop University Hospital; and Gregory DeVore, MD, Fetal Diagnostic Center.

References